Danaher Corp. (NYSE: DHR), the massive D.C. conglomerate of industrial and commercial manufacturers, said Wednesday it has raised $753.7 million euros, or the equivalent of $825.3 million, through the issuance of new shares and will use proceeds to pay off debts, according to a Securities and Exchange commission filing.

The raise was disclosed just days after Danaher finally closed its $21.4 billion acquisition of the biopharma business of General Electric Co.’s life sciences division. Danaher announced its intent to purchase the business in February 2019, and the deal necessitated regulatory approvals in several countries and a substantial stock sale to finance the acquisition.

Image: Danaher Corp. closed its $21.4 billion acquisition of GE's biopharma business March 31. IGOR GOLOVNIOV

There are numerous local and national programs for businesses in need of emergency support, but understanding which options are relevant for your organization can be a challenge.

The Maryland Business Relief Wizard is a tool that helps connect businesses with the resources and programming for which they’re eligible, streamlining the process of finding support.

The Economic Club of Washington, D.C. hosted its fifth virtual event on April 8, 2020. Club President David Rubenstein interviewed economic experts on the state of the economy and the financial forecast. In addition, they discussed the current U.S. and global economy, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the Federal Reserve’s response to the pandemic, and the way forward post COVID-19. Additionally, Dr. Kurt Newman provided a medical update on the evolving virus. The interview took place in three segments.

Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight. The company has a proven track record, partners and extensive networks to advance vaccines or therapeutics quickly toward trials.

Emergent BioSolutions supplies the Strategic National Stockpile with vaccines against anthrax and smallpox, and treatments against anthrax, botulism and smallpox vaccine complications. Its pipeline includes vaccines against Chikungunya and anthrax (again), treatments targeting Zika and Influenza A, and now, COVID-19.

Image: https://www.biospace.com

A new study has begun recruiting at the National Institutes of Health in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), have antibodies to the virus. The presence of antibodies in the blood indicates a prior infection. In this “serosurvey,” researchers will collect and analyze blood samples from as many as 10,000 volunteers to provide critical data for epidemiological models. The results will help illuminate the extent to which the novel coronavirus has spread undetected in the United States and provide insights into which communities and populations are most affected.

Image: Colorized scanning electron micrograph of an apoptotic cell (blue) infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. NIAID

Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® urban office REIT, is the first and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. For more information, please visit www.are.com.

Leading a startup has always been challenging, even under the best conditions. Founders need to quickly master a tremendous range of skills, from building a fantastic product and nailing go-to-market efforts to raising money and managing a board, all while figuring out hiring, culture and compensation. Starting a company is also a lonely endeavor, one that forces founders to make difficult decisions every day with imperfect information. While triaging these challenges, eventually every founder runs headfirst into a problem they haven’t seen before, the kind that leaves them unsure of where to start.

ROCKVILLE, Md. & PROVIDENCE, R.I. & GOLDEN, Colo.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus. Immunomic will work with leaders from EpiVax and PharmaJet, who have a wealth of immunology and vaccine delivery expertise, to rapidly develop its COVID-19 vaccine. Immunomic’s UNITE platform has been widely applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-Cov-2 coronavirus.

Just as many schools around the nation began shuttering for the year last month due to the pandemic, top officials at Children's National Hospital were quickly mounting their own response to address COVID-19 concerns among kids. 

"We heard from our pediatricians in late February, early March that they were very worried about what they were seeing in the community," said Children's National Chief Operating Officer Kathleen Gorman during a virtual roundtable with FierceHealthcare this week.

Image: Here's a look at the advice Children's National had to offer other hospitals about lessons learned from standing up a drive-thru specimen collection site within one week. (Children's National Health System)

The AIM-HI Accelerator Fund’s Women’s Venture Competition is a high-profile initiative among women-led oncology start-up companies or venture teams aspiring to soon establish such firms, in which all participants are offered access to intensive accelerator boot-camp programming by one of the world’s most renowned women entrepreneur accelerator and business training service providers, Springboard Enterprises, and—subject to due diligence and negotiation—the winning business will receive up to $300,000 in AIM-HI investment.

Just three months ago, thousands of biotech types blotted out the streets of San Francisco for the J.P. Morgan Healthcare Conference, four days of crowded rooms, overstuffed bars, and double-booked meetings. Today, with the coronavirus forcing the industry to interact via videoconference, that kind of physical proximity is difficult to imagine. And it might still be unsafe by the time JPM 2021 rolls around.

COVID-19 wasn’t about to stop the important work being done to meet the large unmet need for pediatric medical devices among patients younger than 18. NCC-PDI’s annual “Make Your Medical Device Pitch for Kids!” pitch competition moved to a 100% virtual event format to keep pediatric medical device innovation moving forward while complying with social distancing recommendations that will help to flatten the curve.

In late March, 30 outstanding companies pitched their pediatric device innovations in cardiovascular, orthopedic, spine and Neonatal Intensive Care Unit (NICU) devices — areas where the need is greatest  — to judges in a virtual meeting room setting. 

Image: https://biobuzz.io

Johns Hopkins President Ronald J. Daniels shared a message with the university community today. The full text of the message is below.

Dear Johns Hopkins Faculty, Students, and Staff:

It has been a long and nerve-wracking month since we began to fully prepare for, and mitigate the impact of, the extraordinary challenges posed by COVID-19. Our colleagues from the Bloomberg School of Public Health remind us that we are still likely a few weeks from the peak of the pandemic in Maryland. For the foreseeable future, we will remain under significant strain as we respond in ways that run counter to our normal course of action and to our community's innate desire to connect in person with each other.

Image: https://president.jhu.edu/

A new coronavirus was spreading in the U.S., and with social distancing orders going into place, talk immediately turned to finding a treatment that could stop the spread. In Maryland, companies jumped into action. Work began on a vaccine at Gaithersburg-based Novavax, and the company partnered with Emergent Biosolutions on initial development and manufacturing. Gaithersburg’s Altimmune is also developing a vaccine, and announced plans last week for a preclinical testing collaboration with the University of Alabama Birmingham.

As the U.S. continues to find its way through a tough fight against this global pandemic, a number of BioHealth Capital Region (BHCR) biotech companies are making significant contributions to stem the COVID-19 pandemic. With people across the U.S. and the world making sacrifices to flatten the curve — along with nurses, doctors and first responders who stand heroically at the front lines — life science companies in our region are doing everything in their power to make COVID-19 vaccine progress with celerity, safety and efficacy top-of-mind.

WASHINGTON (NEXSTAR) ─ Even though he says the worst is yet to come, Dr. Anthony Fauci, the nation’s top infectious-disease expert, has seen signs of progress in the country’s fight against the coronavirus.

“The next week we’re going to see a spike in deaths throughout the country, particularly in the hot spot areas like New York, but simultaneously with that, we’re starting to see some cautiously optimistic type signs,” Fauci said.

Image: https://fox8.com

Like many states across the nation, Maryland is preparing for a possible surge of COVID-19 patients.  Johns Hopkins is working with the state and the University of Maryland to erect an Alternate Care Site at the Baltimore Convention Center (ACS BCC). The ACS BCC is planned to open by mid-April and is intended to be used as a post-acute treatment facility.

Johns Hopkins is working on the recruitment, contracting, and credentialing of temporary Physicians and Advanced Practitioners. Compensation will be provided. We are reaching out to you, as a leader within your organization, in hopes that you might forward this to interested parties who may be willing to temporarily assist in treating patients recovering from COVID-19. Please see the attached job posting for details.

Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs through video conference on one of the following dates: 4/22, 5/20. (45 minute blocks of time beginning at 9:00 in the morning.)

Pre-registration is required; sign up here:

For questions/more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it..

BioHealth Capital Region COVID19 Resources:

In these uncertain times, we are proud to have so many BioHealth Capital Region federal, state, local and private sector organizations focused on combatting COVID19.  Please use these links to stay abreast of the last news and resources available for your business.

District of Columbia 

Maryland

• Governor's Update - https://governor.maryland.gov/coronavirus/
• General Update - https://coronavirus.maryland.gov/
• Business Resources - https://govstatus.egov.com/md-coronavirus-business\

Montgomery County, MD

Virginia

US Small Business Administration 

Volunteers

Sean M. Kirk, Executive Vice President, Manufacturing and Technical Operations at Emergent BioSolutions joins Rich Bendis to discuss the COVID-19 Health Crisis, Emergent’s Capabilities in Manufacturing in the BioHealth Capital Region and Beyond

Mr. Kirk joined Emergent BioSolutions in 2003 and has served as executive vice president, manufacturing and technical operations since April 2019. Prior to this position, Mr. Kirk has held various senior leadership roles including senior vice president, manufacturing operations and contract development and manufacturing operations (CDMO) business unit lead from April 2017 to March 2019, senior vice president, biodefense operations from November 2015 to March 2017, senior vice president, biosciences operations from February 2014 to November 2015 and senior vice president, biodefense vaccines and therapeutics development from March 2012 to February 2014. Mr. Kirk also served in multiple roles of increasing responsibility at Emergent’s manufacturing operations site in Lansing, Michigan.

Before joining Emergent, Mr. Kirk worked at Merial, a multinational animal health company, serving in various positions from 1996 to 2001. Mr. Kirk received both an M.B.A. and B.S. in Microbiology from the University of Georgia.

New Members Continue GSK and NEA’s commitment to the BHI mission and the BioHealth Capital Region

ROCKVILLE, MARYLAND, April 6, 2020 – The Board of Directors of BioHealth Innovation, Inc. (BHI) unanimously approved the appointments of two new board members, Rebecca Farkas, PhD, Director, External R&D, Scientific Collaborations at GSK, and Sara Nayeem, M.D., Partner at New Enterprise Associates (NEA). BHI’s leadership also thanked outgoing Board of Directors members Rip Ballou of GSK and David Mott of NEA for their contributions to the organization and friendship of many years.

 “I am honored to welcome both Rebecca and Sara to our Board of Directors,” said Richard Bendis, BHI President and CEO. “They both bring a combination of experience and fresh vision to our already robust collection of industry leaders. We are excited to to work with them to help grow the BioHealth Capital Region industry cluster.”

Immunomic Therapeutics Inc. is pivoting, as many are, in this new era to work on a vaccine for the novel coronavirus. But it’s also pursuing goals that would be considered ambitious even before the world changed: It’s closing in on a $50 million raise, advancing its brain cancer program — and positioning itself for an initial public offering.

The Rockville vaccine maker secured the first $10 million of this latest fundraising round at the end of January from Korean investment group HLB, and it expects to close on another $40 million-plus in the next couple of weeks, said Bill Hearl, founder and CEO of ITI. That capital would support the immuno-oncology company’s therapy for glioblastoma, an aggressive brain cancer, now heading into a phase 2 clinical trial after a successful phase 1 study that extended the typical 14- to 16-month median survival rate to 41 months.

Image: Bill Hearl is CEO and founder of Immunomic Therapeutics in Rockville. COURTESY IMMUNOMIC THERAPEUTICS

Not long ago, working from home was an option for some of us.

Today, it’s the norm for nearly all of us. 

Unless your job absolutely requires you to be on the front lines, the coronavirus pandemic has caused us all to set up home offices and social distance ourselves from coworkers and clients alike. 

That shift has likely carried some stumbling blocks, something even the most seasoned remote worker can attest to.

Image: https://www.bizjournals.com

GlaxoSmithKline and AstraZeneca are considering forming a joint laboratory to help the U.K. government stretch and expand its supplies for COVID-19 diagnostic tests, according to a report from Bloomberg.

Even though diagnostics are not their core efforts, the plan is for the two Big Pharmas to test a range of different reagents, chemical mixtures and other materials for new ways to help detect the spreading novel coronavirus. Successes would be provided to other manufacturers or the U.K.’s National Health Service.

Image: Global supplies of testing reagents and other materials, including swabs, have been faced with overwhelming demand in recent weeks. (NIAID - Rocky Mountain Laboratories)

We're currently tracking 95 potential treatments and 52 potential vaccines in the pipeline to combat hashtag#COVID19.

There are thousands of researchers all over the world racing to get a treatment or vaccine to market.

The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. Due to the potential exceptional impact, we want to assure our recipient community that NIH will be doing our part to help you continue your research.

SAN FRANCISCO--(BUSINESS WIRE)-- venBio Partners LLC today announced the closing of venBio Global Strategic Fund III (“venBio Fund III”), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.

ROCKVILLE, Md., April 6, 2020 /PRNewswire/ -- Emmes today announced that Heather Hill, Dr. Adam Mendizabal and Dr. Nilay Shah have been promoted to vice president.  According to Dr. Anne Lindblad, president and chief executive officer, "These promotions reflect their talent and value to the organization.  Heather, Adam and Nilay demonstrate our commitment to developing staff and promoting from within.  They will strengthen and add great value to our leadership team and will support our plans to grow both internally and externally."

Heather Hill

Dr. Adam Mendizabal

Dr. Nilay Shah

One of America’s biggest companies has teamed up with one of the country’s least-known federal agencies to make doses of a coronavirus vaccine. Lots of them. 

The deal underscores the important role that the U.S. Biomedical Advanced Research and Development Authority, or BARDA, plays behind the scenes in protecting Americans—and everyone, really—from pandemics.

A few weeks ago, I was in New Orleans for a jam-packed wedding weekend, complete with a crawfish boil, second line parade, Hawaii-themed 30th birthday luau for the bride-to-be, and more gumbo and jambalaya than we could eat (and guys, we’re talking authentic Louisiana Creole, which was just delicious.)

Image: Image via the Business Journals

Last week, we spoke to the head of Emergent BioSolutions’ Therapeutics Business Unit Dr. Laura Saward about her company’s work developing plasma-based potential treatments for COVID-19. Now, the company announced that it has received $14.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services (HHS), to speed the development of one of its treatment candidates.

The U.S. Food and Drug Administration approved a clinical trial Friday that will allow Johns Hopkins University researchers to test a therapy for COVID-19 that uses plasma from recovering patients.

Arturo Casadevall, a Johns Hopkins infectious disease expert, proposed the use of convalescent plasma to treat critically ill COVID-19 patients and to boost the immune systems of health care providers and first responders. He assembled a team of physicians and scientists from around the United States to establish a network of hospitals and blood banks that can collect, isolate, and process blood plasma from COVID-19 survivors

COVID-19 Notice for Maryland SBDC Clients, Stakeholders, and Partners

We are committed to serving our clients during the COVID-19 (Coronavirus) health emergency.

Consulting Services - New clients already in business can request COVID consulting assistance by clicking on the "I'M IN BUSINESS- GET CONSULTING" on our home page. The link is right below this notice towards the right side of the page. Continuing clients may continue to contact their consultant by phone, web conference, or email.

Training - All in-person training scheduled during the month of April has been canceled, postponed or offered online. If a paid training class is canceled or postponed, participants may request a refund or apply the funds to another class. If the class will be offered online, registered participants will receive an email with instructions for participating in the online class.

We're proud to announce a partnership with the U.S. Government on a comprehensive response to expedite development of our plasma-derived therapy to address hashtag#COVID19. https://lnkd.in/eHGC5F6

hashtag#toprotectandenhance hashtag#emergentbiosolutions hashtag#COVID19 hashtag#coronavirus

Image: https://www.linkedin.com